Hovione Successfully Completes Phase II Trial of Minocycline Ophthalmic

News
Article

Hovione has successfully completed the Phase II clinical trial of its ophthalmic formulation of minocycline, Meizuvo.

Hovione has successfully completed the Phase II clinical trial of its ophthalmic formulation of minocycline, Meizuvo, aimed at the treatment of dry eye caused by Meibomian Gland Dysfunction (MGD). The company announced the trial completion at the Ophthalmology Innovation Summit Dry Eye Showcase.

Meizuvo is the first ophthalmic formulation of minocycline in clinical development and targets MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic. The Phase II trial, which included 270 patients across 26 clinical sites, assessed two different strengths of minocycline against vehicle in a 1:1:1 randomization.

The trial results demonstrated a statistically significant improvement in the Visual Analogue Scale (VAS) discomfort greater than 50% by the end of treatment for more than two thirds (70%) of patients with positive inflammatory biomarker at baseline. Additionally, a statistically significant improvement in inferior Cornea Fluorescein Staining was seen with both treatment arms versus vehicle at day 57. The product was found to be safe and well-tolerated with less than 3% of patients reporting blurring vision or eye irritation.

“The correlation between the patients with a positive MMP-9 assay at baseline and the clinical improvement observed in both signs and symptoms of dry-eye was groundbreaking,” said Carla Vozone, vice-president of the innovative proprietary portfolio at Hovione in a March 17, 2021 press release.

“We were thrilled with the opportunity to work on this exciting project. Minocycline is a well-known molecule for ophthalmologists and there is significant excitement from the ophthalmology community regarding the potential for a topical alternative,” added George Magrath, CEO of Lexitas Pharma Services, in the press release. “The results in the overall population were encouraging in both signs and symptoms. The results in the inflamed group of subjects were impressive with consistent statistically significant results in key dry eye signs and symptoms.”

Source: Hovione

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content